This is the interesting bit.
International consensus guidelines6,9 recommend that anti-resorptive therapy should be initiated in AI-treated women not fulfilling the above criteria if the lowest BMD T-score is ā¤ā2.0 or if more than two fracture risk factors are present, and be considered where there is a >5ā10% decrease in BMD in one year of AI treatment, or 10-year absolute risk of a major osteoporotic fracture of >20%, or of a hip fracture of >3%. However, this is outside current PBS of Australia subsidy criteria.